A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer

被引：3
|
作者：
Yamashita, Toshinari [1 ]
Shimomura, Akihiko [2 ]
Takano, Toshimi [3 ]
Sagara, Yasuaki [4 ]
Watanabe, Junichiro [5 ]
Tokunaga, Eriko [6 ]
Kikumori, Kunika [7 ]
Kamiyama, Emi [7 ]
Kamio, Takahiro [7 ]
Nakamura, Ryo [7 ]
Shinkai, Tetsu [8 ]
Takahashi, Shunji [9 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Toranomon Gen Hosp, Tokyo, Japan
[4] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Shonan Tobu Sougou Hosp, Kamakura, Kanagawa, Japan
[9] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-12
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator's choice in HER2-low breast cancer.
    Modi, Shanu
    Ohtani, Shoichiro
    Lee, Caleb C.
    Wang, Kongming
    Saxena, Kapil
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [23] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02)
    Andre, Fabrice
    Shahidi, Javad
    Lee, Caleb
    Wang, Kongming
    Krop, Ian E.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Yoshino, T.
    Iwata, H.
    Tamura, K.
    Takahashi, S.
    Redfern, C.
    Modi, S.
    Doi, T.
    Kawakami, H.
    Taniguchi, H.
    Takashima, A.
    Yamaguchi, K.
    Fisher, J.
    Li, B.
    Saito, K.
    Fujisaki, Y.
    Sugihara, M.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Ohba, Akihiro
    Morizane, Chigusa
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ueno, Makoto
    Kobayashi, Satoshi
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Furuse, Junji
    Okano, Naohiro
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
    Modi, S.
    Tsurutani, J.
    Tamura, K.
    Park, H.
    Sagara, Y.
    Murthy, R.
    Iwata, H.
    Krop, I. E.
    Doi, T.
    Redfern, C.
    Moreno-Aspitia, A.
    Redman, R.
    Lee, C.
    Sugihara, M.
    Fujisaki, Y.
    Takahashi, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, F.
    Anoka, C.
    Dobrowolska, A.
    Chaudhry, A.
    Rowbottom, J.
    Gustavson, M.
    Puvvada, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1253 - S1254
  • [28] Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer
    Iwasa, Satoru
    Shitara, Kohei
    Takahashi, Shunji
    Park, Haeseong
    Kadowaki, Shigenori
    Modi, Shanu
    Nonagase, Yoshikane
    Tamura, Kenji
    Yamaguchi, Kensei
    Muro, Kei
    Tsurutani, Junji
    Shahidi, Javad
    Lee, Caleb C.
    Sugihara, Masahiro
    Kawaguchi, Yoshinori
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [29] EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.
    Kamiyama, E.
    Garimella, T.
    Bang, Y.
    Takahashi, S.
    LaCreta, F.
    Ishizuka, H.
    Abutarif, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S69 - S69
  • [30] Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Komatsu, Yoshito
    Esaki, Taito
    Chung, Ki
    Wainberg, Zev
    Sartore-Bianchi, Andrea
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    LANCET ONCOLOGY, 2021, 22 (06): : 779 - 789
12345